BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 31938346)

  • 1. Next-generation proteasome inhibitor oprozomib enhances sensitivity to doxorubicin in triple-negative breast cancer cells.
    Shi Y; Bieerkehazhi S; Ma H
    Int J Clin Exp Pathol; 2018; 11(5):2347-2355. PubMed ID: 31938346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second-generation proteasome inhibitor carfilzomib enhances doxorubicin-induced cytotoxicity and apoptosis in breast cancer cells.
    Shi Y; Yu Y; Wang Z; Wang H; Bieerkehazhi S; Zhao Y; Suzuk L; Zhang H
    Oncotarget; 2016 Nov; 7(45):73697-73710. PubMed ID: 27655642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Second-Generation Proteasome Inhibitor and Doxorubicin Modulates IL-6, pSTAT-3 and NF-kB Activity in MDA-MB-231 Breast Cancer Cells.
    Vyas D; Lopez-Hisijos N; Shah P; Deshpande KS; Basson MD; Vyas A; Chaturvedi LS
    J Nanosci Nanotechnol; 2017 Jan; 17(1):175-85. PubMed ID: 29617099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next-generation proteasome inhibitor MLN9708 sensitizes breast cancer cells to doxorubicin-induced apoptosis.
    Wang H; Yu Y; Jiang Z; Cao WM; Wang Z; Dou J; Zhao Y; Cui Y; Zhang H
    Sci Rep; 2016 May; 6():26456. PubMed ID: 27217076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apatinib-induced NF-κB inactivation sensitizes triple-negative breast cancer cells to doxorubicin.
    Tang D; Ma J; Chu Z; Wang X; Zhao W; Zhang Q
    Am J Transl Res; 2020; 12(7):3741-3753. PubMed ID: 32774731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P-Glycoprotein Inhibition Sensitizes Human Breast Cancer Cells to Proteasome Inhibitors.
    Deshmukh RR; Kim S; Elghoul Y; Dou QP
    J Cell Biochem; 2017 May; 118(5):1239-1248. PubMed ID: 27813130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TAK1 inhibitor NG25 enhances doxorubicin-mediated apoptosis in breast cancer cells.
    Wang Z; Zhang H; Shi M; Yu Y; Wang H; Cao WM; Zhao Y; Zhang H
    Sci Rep; 2016 Sep; 6():32737. PubMed ID: 27599572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
    Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y
    Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interference KRT17 reverses doxorubicin resistance in triple-negative breast cancer cells by Wnt/β-catenin signaling pathway.
    Wu L; Ding W; Wang X; Li X; Yang J
    Genes Genomics; 2023 Oct; 45(10):1329-1338. PubMed ID: 37634232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated estrogen receptor β expression in triple negative breast cancer cells is associated with sensitivity to doxorubicin by inhibiting the PI3K/AKT/mTOR signaling pathway.
    Lei S; Fan P; Wang M; Zhang C; Jiang Y; Huang S; Fang M; He Z; Wu A
    Exp Ther Med; 2020 Aug; 20(2):1630-1636. PubMed ID: 32742395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma.
    Vandewynckel YP; Coucke C; Laukens D; Devisscher L; Paridaens A; Bogaerts E; Vandierendonck A; Raevens S; Verhelst X; Van Steenkiste C; Libbrecht L; Geerts A; Van Vlierberghe H
    Oncotarget; 2016 Jun; 7(23):34988-5000. PubMed ID: 27167000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alcohol promotes migration and invasion of triple-negative breast cancer cells through activation of p38 MAPK and JNK.
    Zhao M; Howard EW; Parris AB; Guo Z; Zhao Q; Yang X
    Mol Carcinog; 2017 Mar; 56(3):849-862. PubMed ID: 27533114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer.
    Salaroglio IC; Gazzano E; Abdullrahman A; Mungo E; Castella B; Abd-Elrahman GEFA; Massaia M; Donadelli M; Rubinstein M; Riganti C; Kopecka J
    J Exp Clin Cancer Res; 2018 Nov; 37(1):286. PubMed ID: 30482226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Piperlongumine Induces Apoptosis and Synergizes with Doxorubicin by Inhibiting the JAK2-STAT3 Pathway in Triple-Negative Breast Cancer.
    Chen D; Ma Y; Li P; Liu M; Fang Y; Zhang J; Zhang B; Hui Y; Yin Y
    Molecules; 2019 Jun; 24(12):. PubMed ID: 31242627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin α3 in triple-negative breast cancer.
    Dai W; Yang F; Ma L; Fan Y; He B; He Q; Wang X; Zhang H; Zhang Q
    Biomaterials; 2014 Jul; 35(20):5347-5358. PubMed ID: 24726747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis.
    Guan S; Zhao Y; Lu J; Yu Y; Sun W; Mao X; Chen Z; Xu X; Pan J; Sun S; Yang J
    Oncotarget; 2016 Nov; 7(46):75914-75925. PubMed ID: 27713150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro to Clinical Translation of Combinatorial Effects of Doxorubicin and Abemaciclib in Rb-Positive Triple Negative Breast Cancer: A Systems-Based Pharmacokinetic/Pharmacodynamic Modeling Approach.
    Fleisher B; Lezeau J; Werkman C; Jacobs B; Ait-Oudhia S
    Breast Cancer (Dove Med Press); 2021; 13():87-105. PubMed ID: 33628047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis.
    Das S; Tripathi N; Siddharth S; Nayak A; Nayak D; Sethy C; Bharatam PV; Kundu CN
    Apoptosis; 2017 Oct; 22(10):1205-1224. PubMed ID: 28702823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The new-generation proteasome inhibitor oprozomib increases the sensitivity of cervical cancer cells to cisplatin-induced apoptosis.
    Li QZ; Sun LP; Shi HY; Chen Y; Shen H
    J Biol Regul Homeost Agents; 2021; 35(2):559-569. PubMed ID: 33973461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin.
    Inao T; Iida Y; Moritani T; Okimoto T; Tanino R; Kotani H; Harada M
    Oncotarget; 2018 May; 9(39):25545-25556. PubMed ID: 29876007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.